New Investment from Forbion and Sofinnova Partners MANCHESTER, England, Aug. 4, 2022 /PRNewswire/ F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development
Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net